comparemela.com

Latest Breaking News On - Biotech investing - Page 5 : comparemela.com

BELLUS Health to Participate in the Cowen & Co 42nd Annual Health Care Conference

BELLUS Health Inc. a clinical-stage biopharmaceutical company developing novel therapeutics for the treatment of refractory chronic cough and other cough hypersensitivity indications, today announced that Roberto Bellini, BELLUS Health s President and Chief Executive Officer, will participate in a panel at the Cowen & Co. 42 nd Annual Health Care Conference. Panel Details: Event: Cowen & Co. 42 nd Annual Health Care .

Gilead Receives Complete Response Letter From U S FDA for Investigational Lenacapavir Due to Vial Compatability Issues

CRL Cites Issues Related to Compatibility of Vials and Lenacapavir Solution – – No New Clinical Studies Requested in the CRL – Gilead Sciences, Inc. today announced the U.S. Food and Drug Administration has issued a complete response letter for the New Drug Application for lenacapavir, an investigational, long-acting HIV-1 capsid inhibitor under review for the treatment of HIV-1 infection in heavily .

BriaCell Adds Two Clinical Trial Sites to Accelerate Patient Enrollment

BriaCell Therapeutics Corp. a clinical-stage biotechnology company specializing in targeted immunotherapies for advanced breast cancer, announces that it has recruited two additional clinical sites for screening and enrolling advanced breast cancer patients in the Phase IIIa combination study of BriaCell’s lead candidate, Bria-IMT™, with Incyte’s checkpoint inhibitor, retifanlimab, and its immunomodulator, .

Boosh Arranges $2,000,000 Non-Brokered Private Placement

Boosh Plant-Based Brands Inc.  announces that it intends to raise, on a non-brokered basis, aggregate gross proceeds of up to $2,000,000 through the issuance up to 2,857,142 units at a price of $0.70 per Unit . Each Unit will comprise one common share and one share purchase warrant. Each whole warrant will entitle the holder to acquire an additional common share at a price of $1.00 per share for a period of 36 .

Aurinia Pharmaceuticals to Present at Upcoming January Investor Conferences

Aurinia Pharmaceuticals Inc. today announced that members of the management team will participate in two upcoming virtual investor conferences. H.C. Wainwright Virtual BioConnect 2022 Conference. On-demand presentation available Monday, January 10, 2022, beginning at 7:00 a.m. EST thru Thursday, January 13, 2022 J.P Morgan 40 th Annual Healthcare Conference. Presentation to be hosted on Thursday, January 13, 2022 at .

© 2025 Vimarsana

vimarsana © 2020. All Rights Reserved.